Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport ® in the treatment of Adults suffering from Upper Limb Spasticity

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023